ALXN1920
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 06, 2025
AUTUMN: Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
(clinicaltrials.gov)
- P2 | N=30 | Not yet recruiting | Sponsor: Alexion Pharmaceuticals, Inc.
New P2 trial • Glomerulonephritis • Renal Disease
December 13, 2023
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Alexion Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed
Trial completion
November 15, 2023
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: Alexion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2024 ➔ Dec 2023
Enrollment closed • Trial completion date
May 01, 2023
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Alexion | Not yet recruiting ➔ Recruiting
Enrollment open
March 02, 2023
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Alexion
New P1 trial
1 to 5
Of
5
Go to page
1